JP2023540444A - 治療用抗体 - Google Patents
治療用抗体 Download PDFInfo
- Publication number
- JP2023540444A JP2023540444A JP2023507798A JP2023507798A JP2023540444A JP 2023540444 A JP2023540444 A JP 2023540444A JP 2023507798 A JP2023507798 A JP 2023507798A JP 2023507798 A JP2023507798 A JP 2023507798A JP 2023540444 A JP2023540444 A JP 2023540444A
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- seq
- antibody
- sequence identity
- ox40l
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB2012331.1 | 2020-08-07 | ||
| GBGB2012331.1A GB202012331D0 (en) | 2020-08-07 | 2020-08-07 | Therapeutic antibodies |
| PCT/GB2021/052043 WO2022029447A1 (en) | 2020-08-07 | 2021-08-06 | Therapeutic antibodies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023540444A true JP2023540444A (ja) | 2023-09-25 |
| JP2023540444A5 JP2023540444A5 (cg-RX-API-DMAC7.html) | 2026-02-02 |
Family
ID=72520053
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023507798A Pending JP2023540444A (ja) | 2020-08-07 | 2021-08-06 | 治療用抗体 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20230272097A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4192867A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023540444A (cg-RX-API-DMAC7.html) |
| CN (1) | CN116249710A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021319941A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3186391A1 (cg-RX-API-DMAC7.html) |
| GB (1) | GB202012331D0 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022029447A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017189805A1 (en) | 2016-04-27 | 2017-11-02 | Abbvie Inc. | Methods of treatment of diseases in which il-13 activity is detrimental using anti-il-13 antibodies |
| US10093731B2 (en) | 2017-02-24 | 2018-10-09 | Kindred Biosciences, Inc. | Anti-IL31 antibodies for veterinary use |
| JP7671275B2 (ja) | 2019-08-29 | 2025-05-01 | エランコ・ユーエス・インコーポレイテッド | 動物用の抗il31抗体 |
| US20220332837A1 (en) * | 2021-04-08 | 2022-10-20 | Colorado State University Research Foundation | Methods and compositions for ox40 activation in treatment of canine cancer |
| WO2023152486A1 (en) * | 2022-02-09 | 2023-08-17 | Petmedix Ltd | Therapeutic antibodies |
| GB202217978D0 (en) * | 2022-11-30 | 2023-01-11 | Petmedix Ltd | Rodents expressing a common light chain |
| KR20250137204A (ko) | 2022-12-27 | 2025-09-17 | 인베티엑스 인코포레이티드 | 신생아 fc 수용체(fcrn)에 대한 결합이 변경된 폴리펩타이드 및 사용 방법 |
| CN121002059A (zh) | 2023-01-20 | 2025-11-21 | 因外泰克斯公司 | 用于伴侣动物的双特异性结合剂 |
| US20250257142A1 (en) * | 2024-02-13 | 2025-08-14 | Invetx, Inc. | Anti-il-31ra antibodies and uses thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007530045A (ja) * | 2004-03-23 | 2007-11-01 | アムジエン・インコーポレーテツド | ヒトox40l(cd134l)特異性モノクローナル抗体 |
| US20170137843A1 (en) * | 2012-02-14 | 2017-05-18 | Merial, Inc. | Recombinant Poxviral Vectors Expressing both Rabies and OX40 Proteins, and Vaccines Made Therefrom |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
| GB0525662D0 (en) | 2005-12-16 | 2006-01-25 | Glaxo Group Ltd | Immunoglobulins |
| US7812133B2 (en) * | 2005-12-16 | 2010-10-12 | Genentech, Inc | Anti-OX40L antibodies and methods using same |
| KR102119840B1 (ko) | 2011-07-11 | 2020-06-09 | 아이크노스 사이언스 에스. 아. | Ox40에 결합하는 항체 및 이들의 용도 |
| US8790651B2 (en) | 2011-07-21 | 2014-07-29 | Zoetis Llc | Interleukin-31 monoclonal antibody |
| GB201316644D0 (en) | 2013-09-19 | 2013-11-06 | Kymab Ltd | Expression vector production & High-Throughput cell screening |
| US10196435B2 (en) | 2013-11-18 | 2019-02-05 | University Of Southern California | OX40L fusion protein for the immunotherapy of tumors of veterinary animals |
| PL3265123T3 (pl) | 2015-03-03 | 2023-03-13 | Kymab Limited | Przeciwciała, zastosowania i sposoby |
| GB2561352B (en) | 2017-04-10 | 2023-01-18 | Genome Res Ltd | Animal models and therapeutic molecules |
| JP7449234B2 (ja) | 2018-03-16 | 2024-03-13 | ゾエティス・サービシーズ・エルエルシー | 獣医学使用のためのインターロイキン31モノクローナル抗体 |
| GB2578867A (en) | 2018-10-09 | 2020-06-03 | Genome Res Ltd | Animal models and therapeutic molecules |
-
2020
- 2020-08-07 GB GBGB2012331.1A patent/GB202012331D0/en not_active Ceased
-
2021
- 2021-08-06 WO PCT/GB2021/052043 patent/WO2022029447A1/en not_active Ceased
- 2021-08-06 AU AU2021319941A patent/AU2021319941A1/en active Pending
- 2021-08-06 EP EP21758732.8A patent/EP4192867A1/en active Pending
- 2021-08-06 US US18/007,314 patent/US20230272097A1/en active Pending
- 2021-08-06 JP JP2023507798A patent/JP2023540444A/ja active Pending
- 2021-08-06 CA CA3186391A patent/CA3186391A1/en active Pending
- 2021-08-06 CN CN202180058009.6A patent/CN116249710A/zh active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007530045A (ja) * | 2004-03-23 | 2007-11-01 | アムジエン・インコーポレーテツド | ヒトox40l(cd134l)特異性モノクローナル抗体 |
| US20170137843A1 (en) * | 2012-02-14 | 2017-05-18 | Merial, Inc. | Recombinant Poxviral Vectors Expressing both Rabies and OX40 Proteins, and Vaccines Made Therefrom |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021319941A1 (en) | 2023-02-16 |
| GB202012331D0 (en) | 2020-09-23 |
| WO2022029447A1 (en) | 2022-02-10 |
| CN116249710A (zh) | 2023-06-09 |
| EP4192867A1 (en) | 2023-06-14 |
| US20230272097A1 (en) | 2023-08-31 |
| CA3186391A1 (en) | 2022-02-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230060847A1 (en) | Anti-bcma heavy chain-only antibodies | |
| JP6938383B2 (ja) | イヌインターロイキン4受容体アルファに対する抗体 | |
| US20230272097A1 (en) | Therapeutic antibodies | |
| JP7303126B2 (ja) | 抗bcma重鎖のみ抗体 | |
| JP7254699B2 (ja) | 抗bcma重鎖のみ抗体 | |
| JP2024020377A (ja) | 抗cd38抗体および使用方法 | |
| CA2861793C (en) | Method of providing monoclonal auto-antibodies with desired specificity | |
| US10131709B2 (en) | Nucleic acid molecules encoding monoclonal antibodies specific for IL-22 | |
| WO2017134292A1 (en) | Anti-ox40 antagonistic antibodies for the treatment of atopic dermatitis | |
| CN117986366A (zh) | 拮抗性抗犬pd-1抗体 | |
| JP2024530036A (ja) | 抗体Fcバリアント | |
| US20200247903A1 (en) | Method | |
| CN120842422A (zh) | 一种抗CD30和CD16a的双特异性抗体及其应用 | |
| US20250340659A1 (en) | Therapeutic antibodies | |
| CN118715244A (zh) | 治疗性抗体 | |
| CN121108346B (zh) | 抗ly6g6d单域抗体及其制备方法和用途 | |
| WO2026086936A1 (en) | Uses of multispecific antigen binding proteins capable of binding cd19 and cd3 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20240802 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20250718 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20250729 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20251024 |
|
| A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20260123 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20260123 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20260324 |